| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/05/2009 | US20090060915 Polypeptide, vaccine and use thereof |
| 03/05/2009 | US20090060911 Enhancement of antibody-mediated immune responses |
| 03/05/2009 | US20090060904 Vegetarian Protein A Preparation and Methods Thereof |
| 03/05/2009 | US20090060903 administering Noggin proteins to reduce teratogenicity of antineoplastic agents; antibodies |
| 03/05/2009 | US20090060902 Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
| 03/05/2009 | US20090060901 Detoxification method |
| 03/05/2009 | US20090060899 Composition of organic compounds |
| 03/05/2009 | US20090060897 Systems for enlarging the diameter of a biological conduit in a human subject |
| 03/05/2009 | US20090060896 Gene repair involving in vivo excision of targeting DNA |
| 03/05/2009 | US20090060895 Compositions and Methods of Using Chondroitinase ABCI Mutants |
| 03/05/2009 | US20090060894 Treatment to aid in the metabolism of alcohol |
| 03/05/2009 | US20090060893 Methods for enlarging the diameter of a biological conduit in a human subject |
| 03/05/2009 | US20090060892 Agents for suppressing hepatic fibrosis |
| 03/05/2009 | US20090060891 High Concentration Self-Microemulsifying Coenzyme Q10 Preparations For Nutritional Use |
| 03/05/2009 | US20090060888 Regulated transcription of targeted genes and other biological events |
| 03/05/2009 | US20090060875 HCV Vaccines for Chronic HCV Patients |
| 03/05/2009 | US20090060873 Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris |
| 03/05/2009 | US20090060872 Phosphadiazine hcv polymerase inhibitors v |
| 03/05/2009 | US20090060871 Administration of agonist-antagonist in opioid-dependent patients |
| 03/05/2009 | US20090060870 for treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as human papilloma virus-induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias; measuring or detecting the presence of a CD4+ type 1 T helper (Th1) cell response against an HPV |
| 03/05/2009 | US20090060869 Ejection liquid, ejection method, method of making droplets from liquid, cartridge and ejection device |
| 03/05/2009 | US20090060868 treating or delaying the onset of multiple sclerosis using enteric Alpha-melanocyte stimulating hormone (MSH); soluble immune response suppressor (SIRS) |
| 03/05/2009 | US20090060867 Phosphadiazine hcv polymerase inhibitors iii and vi |
| 03/05/2009 | US20090060866 Phosphadiazine hcv polymerase inhibitors i and ii |
| 03/05/2009 | US20090060865 Mammalian receptor proteins; related reagents and methods |
| 03/05/2009 | US20090060864 administering an antitumor agent containing a combination of an alpha v beta 3 angiogenisis antagonist and an anti-tumor immunotherapeutic agent, which is a fusion protein of a cytokine IL-2 and an Ig heavy chain that immunoreacts with a tumor associated antigen target; drug target |
| 03/05/2009 | US20090060863 Derivatives of growth hormone and related proteins |
| 03/05/2009 | US20090060862 PEGylation by the Dock and Lock (DNL) Technique |
| 03/05/2009 | US20090060861 Stabilized Polypeptide Formulations |
| 03/05/2009 | DE102007041735A1 Use of a multi-functional active substance mixture comprising a peptide fraction and an amino acid fraction, for producing a formulation for regulating the outer skin conditions of mammals including humans |
| 03/05/2009 | DE102007040932A1 Liquid granulocyte colony-stimulating factor formulation, e.g. for treating cancer, neutropenia, HIV infections or neurological disorders, comprises a sugar alcohol, surfactant and acetate buffer |
| 03/05/2009 | CA2698115A1 Treatment of autoimmune disease |
| 03/05/2009 | CA2698100A1 Compositions and methods of using proislet peptides and analogs thereof |
| 03/05/2009 | CA2698013A1 Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| 03/05/2009 | CA2697976A1 A process for producing a peptide hormone |
| 03/05/2009 | CA2697951A1 Amino acid pairing-based self assembling peptides and methods |
| 03/05/2009 | CA2697681A1 Selective cytopheresis devices and related methods thereof |
| 03/05/2009 | CA2697513A1 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
| 03/05/2009 | CA2697501A1 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent |
| 03/05/2009 | CA2697413A1 Modulators of hypersensitivity reactions |
| 03/05/2009 | CA2697376A1 Liquid formulation of g-csf |
| 03/05/2009 | CA2697363A1 Modulation of synaptogenesis |
| 03/05/2009 | CA2697361A1 Alpha-synuclein binding diagnostic agent |
| 03/05/2009 | CA2697108A1 Mutant double cyclized receptor peptides inhibiting .beta.1-adrenoceptor antibodies |
| 03/05/2009 | CA2695559A1 Neuroprotection using nap-like and sal-like peptide mimetics |
| 03/05/2009 | CA2693707A1 B7-dc variants |
| 03/04/2009 | EP2031076A1 Novel compositions and methods for cancer |
| 03/04/2009 | EP2031062A1 Dna encoding polypeptide capable of modulating muscle-specific tyrosine kinase activity |
| 03/04/2009 | EP2031057A1 SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME |
| 03/04/2009 | EP2031056A1 Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 03/04/2009 | EP2031054A1 Fusion protein, gene related to fusion protein, vector, transformants, and anti-inflammatory medicinal composition |
| 03/04/2009 | EP2030986A1 Polypeptide derivative of parathyroid hormone (PTH) |
| 03/04/2009 | EP2030982A1 Glycopeptide antibiotic derivative |
| 03/04/2009 | EP2030981A1 Compounds for proteasome enzyme inhibition |
| 03/04/2009 | EP2030631A1 Means and methods for treating peripheral and cardiovascular diseases via modulation of arteriogenesis |
| 03/04/2009 | EP2030629A1 Lipid-metabolism-improving agent |
| 03/04/2009 | EP2030628A1 A peptide for preventing or treating liver damage and its derivant and the use |
| 03/04/2009 | EP2030016A2 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| 03/04/2009 | EP2029743A1 Methods of diagnosing and treating complications of pregnancy |
| 03/04/2009 | EP2029740A1 Use of polysaccharides for promotion of enzymatic activity |
| 03/04/2009 | EP2029738A2 Factor ix analogues having prolonged in vivo half life |
| 03/04/2009 | EP2029624A1 Peptide associated with rheumatic fever (parf) and its use as a diagnostic marker |
| 03/04/2009 | EP2029618A2 Agents, methods and uses |
| 03/04/2009 | EP2029617A2 N-oxides of kappa opioid receptor peptides |
| 03/04/2009 | EP2029231A1 Use of alpha-lactalbumin for regulation of glycemia |
| 03/04/2009 | EP2029171A1 Methods of modulating il-22 and il-17 |
| 03/04/2009 | EP2029162A1 Composition for controlling snoring, in the form of a nasal spray |
| 03/04/2009 | EP2029161A2 Use of non-catalytic form of heparanase and peptides thereof for reversing the anti-coagulant effects of heparinoids |
| 03/04/2009 | EP2029160A2 Methods to restore glycemic control |
| 03/04/2009 | EP2029159A2 Compositions and methods for modulating vascular development |
| 03/04/2009 | EP2029158A1 Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
| 03/04/2009 | EP2029157A2 Abc transporter ligand |
| 03/04/2009 | EP2029156A2 Combination therapy for treatment of cancer |
| 03/04/2009 | EP2029155A2 Improved antitumoral treatments |
| 03/04/2009 | EP2029154A2 Treatment of melanoma |
| 03/04/2009 | EP2029153A2 Hepatitis c serine protease inhibitors and uses therefor |
| 03/04/2009 | EP2029141A2 Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist |
| 03/04/2009 | EP2029123A2 Use of a compound with rankl activity |
| 03/04/2009 | EP2029120A2 Nanoparticles containing three various ligands for providing immune responses against infectious agents |
| 03/04/2009 | EP2029103A2 Vegf antagonist formulations suitable for intravitreal administration |
| 03/04/2009 | EP1740198A4 Anti-aging effects of substance p |
| 03/04/2009 | EP1700120B1 Marker for neuromyelitis optica |
| 03/04/2009 | EP1695983B1 Glucagon-like peptide-1 analogs |
| 03/04/2009 | EP1663236B1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate |
| 03/04/2009 | EP1635816B1 Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases |
| 03/04/2009 | EP1599222B1 Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
| 03/04/2009 | EP1578427B1 Use of gnrh agonists to support the luteal phase during infertility treatment |
| 03/04/2009 | EP1572228A4 Method of inducing maturation of dendritic cells and uses therefor |
| 03/04/2009 | EP1519957B1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 03/04/2009 | EP1515984B1 Peptide derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions |
| 03/04/2009 | EP1499736B1 Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
| 03/04/2009 | EP1463758B1 Mammalian prolactin variants |
| 03/04/2009 | EP1432738B1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 03/04/2009 | EP1418813A4 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| 03/04/2009 | EP1401863B1 Somatostatin-dopamine chimeric analogs |
| 03/04/2009 | EP1379269B1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease |
| 03/04/2009 | EP1294876B1 Eg-vegf nucleic acids and polypeptides and methods of use |
| 03/04/2009 | EP1255845B1 Modified cytokines for use in cancer therapy |
| 03/04/2009 | EP1252322B2 Herpes virus strains for gene therapy |
| 03/04/2009 | EP1246917B1 Human stra6 polypeptides |